1. Search Result
Search Result
Results for "

FAAH-IN-2

" in MedChemExpress (MCE) Product Catalog:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-79511
    FAAH-IN-2
    1 Publications Verification

    O-DesmorpholINopropyl GefitINib

    FAAH Autophagy Others
    FAAH-IN-2 (O-Desmorpholinopropyl Gefitinib) is a potent FAAH(fatty acid amide hydrolase) inhibitor extracted from Patent WO/2008/100977A2.
    FAAH-IN-2
  • HY-15249
    JZL 184
    3 Publications Verification

    MAGL Neurological Disease
    JZL 184 is a potent, selective and irreversible MAGL inhibitor that blocks 2-Arachidonoylglycerol (2-AG) hydrolysis in brain membranes (IC50 of 8 nM). JZL 184 displays >300-fold selectivity for MAGL over FAAH .
    JZL 184
  • HY-18977
    KML29
    2 Publications Verification

    MAGL Metabolic Disease Inflammation/Immunology
    KML29 is an extremely selective, orally active and irreversible MAGL inhibitor, with IC50 values of 15 nM, 43 nM and 5.9 nM for mouse, rat and human MAGL, respectively. KML29 exhibits minimal cross-reactivity toward other central and peripheral serine hydrolases, including no detectable activity against FAAH .
    KML29
  • HY-152253

    FAAH Cannabinoid Receptor Infection Neurological Disease Inflammation/Immunology Cancer
    CB2R/FAAH modulator-2 (compound 26) is a dual targeting modulator that acts as a CB2R agonist and FAAH inhibitor. The Ki values for CB2R/FAAH modulator-2 are 10.8 and 152.9 nM for CB2R and CB1R, respectively, and the IC50 value for FAAH is 6.2 μM. CB2R/FAAH modulator-2 can be used in studies related to cancer, deleterious inflammatory cascades occurring in neurodegenerative diseases, and COVID-19 infection .
    CB2R/FAAH modulator-2
  • HY-139384

    FAAH Neurological Disease
    FAAH inhibitor 2 (Compound 17b) is an irreversible fatty acid amide hydrolase (FAAH) inhibitor, with an IC50 of 0.153 μM .
    FAAH inhibitor 2
  • HY-149654

    FAAH Phospholipase Neurological Disease Inflammation/Immunology
    FAAH/cPLA2α-IN-1 is a dual inhibitor of FAAH and cPLA2α with IC50s of 32 and 47 nM, respectively .
    FAAH/cPLA2α-IN-1
  • HY-103339

    FAAH MAGL Neurological Disease
    VDM11 is a potent and selective anandamide membrane transporter (AMT) inhibitor . VDM11 inhibits FAAH and MAGL and may act as an alternative FAAH substrate .
    VDM11
  • HY-W728451

    FAAH Cardiovascular Disease Neurological Disease
    URB694 is a carbamate FAAH inhibitor that irreversibly carbamoylate the nucleophile catalytic serine in FAAH active site. URB694 exhibits antidepressant-like activity and cardioprotective effects. URB694 can be used to prepare 11C-Carbonyl-URB694 for in vivo positron emission tomography (PET) imaging studies of the brain FAAH .
    URB694
  • HY-124744

    FAAH Neurological Disease
    ASP 8477 is an orally active and selective fatty acid amide hydrolase (FAAH) inhibitor with IC50 values ​​of 3.99, 1.65, and 57.3 nM for human FAAH-1, FAAH-1 (P129T), and FAAH-2, respectively. ASP 8477 has central nervous system activity and can be used in analgesia research .
    ASP 8477

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: